New CAR t cocktail aims to tackle Hard-to-Treat myeloma

NCT ID NCT04855136

Terminated Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so results are limited, but it provides initial safety and effectiveness data for these combination approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bb2121 (ide-cel) CAR T cell therapy combined with CC-220 or BMS-986405
What this could lead to: If successful, this could point toward a more effective treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early, small trial (21 participants) that was terminated, so results are limited. CAR T therapy carries risks like severe immune reactions and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Local Institution - 101

Jacksonville, Florida, 32224-1865, United States
Local Institution - 103

Nashville, Tennessee, 37203, United States
Local Institution - 104

Atlanta, Georgia, 30322, United States
Local Institution - 107

Houston, Texas, 77030, United States
Local Institution - 108

Boston, Massachusetts, 02117, United States
Local Institution - 109

Hackensack, New Jersey, 07601, United States
Local Institution - 110

New York, New York, 10032, United States
Local Institution - 111

Charlotte, North Carolina, 28204, United States
Local Institution - 113

San Francisco, California, 94143, United States
Local Institution - 114

Chicago, Illinois, 60611, United States
Local Institution - 117

Birmingham, Alabama, 10016, United States
Local Institution - 118

Philadelphia, Pennsylvania, 19107, United States
Local Institution - 120

Atlanta, Georgia, 30342, United States
Local Institution - 124

Boston, Massachusetts, 02215, United States
Local Institution - 201

Pamplona, 31008, Spain
Local Institution - 202

Salamanca, 37007, Spain
New York University Langone

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.